Zimmer Biomet (ZBH) · Medical Devices
Zimmer Biomet Q3 2026 earnings: summary, key numbers & outlook
Results filed 4 Nov 2026 · Quarter ended 30 Sep 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Zimmer Biomet says its diversification strategy is working, as Hips, S.E.T. and Technology & Data grew at upper single or double digits while Knees shrank, and it extended its THINK Surgical robotics deal.
Zimmer Biomet's growth is shifting away from knees. Hips, S.E.T. and Technology & Data, Bone Cement and Surgical grew at upper single-digit or double-digit rates and together make up two-thirds of the business, while Knees declined in both the U.S. and internationally. The company extended its multi-year distribution and supply agreement with THINK Surgical, launched foot and ankle products, and opened a surgeon training facility in Charlotte.
Management is steering toward a broader portfolio, a more comprehensive robotics offering and a reshaped U.S. commercial organization, backed by leadership promotions. It raised its full-year organic growth outlook on this momentum. The main tension is that Knees, the largest category, is still shrinking, and the U.S. sales and distribution transformation and the portfolio rationalization both carry execution risk.
Key numbers
- Net sales · GAAP
- $2.063 billion
- Net earnings · GAAP
- $191.6 million
- Diluted EPS · GAAP
- $1.00
- Adjusted diluted EPS · non-GAAP
- $1.90
- Gross margin · GAAP
- 63.1%
- Operating profit · GAAP
- $307.6M
- Operating profit margin · GAAP
- 14.9%
- Operating cash flow · GAAP
- $560.0 million
increased 3.1% on a reported basis and 3.7% on a constant currency basis
a decrease of 13.8%
consistent with the prior year period
| Segment or metric | Value | Change |
|---|---|---|
| Knees | $767.5M | (3.1)% reported, (2.6)% constant currency |
| Hips | $536.5M | 6.0% reported, 7.0% constant currency |
| S.E.T. | $578.3M | 6.8% reported, 7.1% constant currency |
| Technology & Data, Bone Cement and Surgical | $180.6M | 11.9% reported, 13.0% constant currency |
| United States | $1.2B | 3.6% reported and constant currency |
| International | $857.2M | 2.4% reported, 3.9% constant currency |
Where each number comes from
- Net sales: “Third quarter net sales of $2.063 billion increased 3.1% on a reported basis and 3.7% on a constant currency1 basis”
- Net earnings: “Net earnings for the third quarter were $191.6 million, or $362.8 million on an adjusted1 basis.”
- Diluted EPS: “Diluted earnings per share were $1.00 for the third quarter, a decrease of 13.8%, and adjusted1 diluted earnings per share were $1.90”
- Adjusted diluted EPS: “adjusted1 diluted earnings per share were $1.90, consistent with the prior year period.”
- Gross margin: “Gross margin | 63.1% | 63.2% | 63.7% | 63.4%”
- Operating profit: “Operating Profit | 307.6 | 351.3”
- Operating profit margin: “Operating profit margin | 14.9% | 17.6% | 15.9% | 15.8%”
- Operating cash flow: “Zimmer Biomet generated $560.0 million in operating cash flow and $372.4 million of free cash flow1 in the third quarter.”
- Knees: “Total | 767.5 | (3.1) | (2.6) Hips United States | 280.1 | 5.8 | 5.8”
- Hips: “Total | 536.5 | 6.0 | 7.0 S.E.T. * | 578.3 | 6.8 | 7.1”
- S.E.T.: “Total | 536.5 | 6.0 | 7.0 S.E.T. * | 578.3 | 6.8 | 7.1”
- Technology & Data, Bone Cement and Surgical: “Technology & Data, Bone Cement and Surgical | 180.6 | 11.9 | 13.0”
- United States: “United States | $1,205.6 | 3.6% | 3.6% International | 857.2 | 2.4 | 3.9”
- International: “United States | $1,205.6 | 3.6% | 3.6% International | 857.2 | 2.4 | 3.9”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q3 2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $2.1B | +3.1% | −5.2% |
| Operating income | $307.6M | −12.4% | −5.7% |
| Net income | $191.6M | −17.0% | −3.4% |
| Diluted EPS | $1.00 | −13.8% | −2.9% |
| Free cash flow | $484.2M | +33.1% | +23.0% |
| Operating margin | 14.9% | −2.7 pts | −0.1 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Reported revenue change | year ending December 31, 2026 | 4.4% - 4.9% |
| Constant currency revenue change | year ending December 31, 2026 | 4.1% - 4.6% |
| Organic constant currency revenue change | year ending December 31, 2026 | 3.0% - 3.5% |
| Foreign currency exchange impact | year ending December 31, 2026 | +0.25% |
| Adjusted diluted EPS | year ending December 31, 2026 | $8.50- $8.60 |
Key takeaways
Diversification beyond knees is showing results
Hips, S.E.T. and Technology & Data, Bone Cement and Surgical grew at upper single-digit or double-digit rates and represent two-thirds of the book of business. Management says this validates its diversification strategy.
Knees remain the drag on growth
Knees sales fell 3.1% reported and 2.6% in constant currency, declining in both the U.S. and internationally. As the largest category, it still holds back overall growth.
Robotics partnership with THINK Surgical extended
Zimmer Biomet extended a multi-year limited exclusive distribution and supply agreement with THINK Surgical. It says this reinforces its aim of offering the most comprehensive robotics portfolio.
Foot and ankle portfolio expanded with two launches
The company launched the Megalodon Dynamic Compression System and SmartShot Marrow Access Device. This builds on the faster-growing S.E.T. franchise, which grew 7.1% in constant currency.
U.S. commercial transformation and surgeon education investments
Three leaders were promoted to accelerate the U.S. commercial transformation, and a new Zimmer Biomet Institute facility opened in Charlotte covering robotics and AI-enabled technologies. Management cites commercial execution as a driver of results.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $2.0B * |
| Q1 2025 | $1.9B |
| Q2 2025 | $2.1B |
| Q3 2025 | $2.0B |
| Q4 2025 | $2.2B * |
| Q1 2026 | $2.1B |
| Q2 2026 | $2.2B |
| Q3 2026 | $2.1B |
Data
| Q1 2025 | $0.91 |
| Q2 2025 | $0.77 |
| Q3 2025 | $1.16 |
| Q1 2026 | $1.22 |
| Q2 2026 | $1.03 |
| Q3 2026 | $1.00 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 19.2% |
| Q1 2025 | 15.3% |
| Q2 2025 | 14.4% |
| Q3 2025 | 17.6% |
| Q4 2025 | 6.9% |
| Q1 2026 | 17.9% |
| Q2 2026 | 15.0% |
| Q3 2026 | 14.9% |
Data
| Q4 2024 | $454.8M |
| Q1 2025 | $338.2M |
| Q2 2025 | $328.1M |
| Q3 2025 | $363.7M |
| Q4 2025 | $442.6M |
| Q1 2026 | $323.1M |
| Q2 2026 | $393.6M |
| Q3 2026 | $484.2M |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
Where is Zimmer Biomet's growth coming from?
Hips, S.E.T. and Technology & Data, Bone Cement and Surgical grew at upper single-digit or double-digit rates and make up two-thirds of its book of business. Technology & Data, Bone Cement and Surgical grew fastest at 13.0% in constant currency.
How are knees performing?
Knees sales declined 3.1% reported and 2.6% in constant currency in the quarter. Both the U.S. (down 2.0%) and international (down 3.4% constant currency) fell.
What is Zimmer Biomet doing in robotics?
It extended a multi-year limited exclusive distribution and supply agreement with THINK Surgical. The company says this supports offering the most comprehensive robotics portfolio.
What new products did the company launch?
It launched the Megalodon Dynamic Compression System and SmartShot Marrow Access Device, expanding its foot and ankle portfolio.
How did management change its 2026 outlook?
It raised full-year organic constant-currency growth guidance to 3.0% - 3.5% from 2.25% - 3.25%. It also raised adjusted EPS guidance to $8.50- $8.60 from $8.47 - $8.59.
Documents
SEC filing
Call recording
Call recording on YouTube ↗. Official replay ↗.